Evidence map›Paper›PMID 37300641›Full record

ArticleJournal of epidemiology and global health2023

Assessment of the Impact of the Rotavirus Vaccine Against Severe Rotaviral Diarrhea in Uzbekistan.

Erkin Musabaev, Umed Ismailov, Nargiz Ibadullaeva, Aziza Khikmatullaeva, Ilham Norbaev, Umar Primov, Dilorom Ahrarova, Saidkhon Sharapov, Ulugbek Yusupov, Renat Latipov

Abstract read
In one paragraph

Article in Journal of epidemiology and global health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Erkin MusabaevResearch Institute of Virology, Tashkent, Uzbekistan.
Umed IsmailovResearch Institute of Virology, Tashkent, Uzbekistan.
Nargiz IbadullaevaResearch Institute of Virology, Tashkent, Uzbekistan. drnargizis@gmail.com.
Aziza KhikmatullaevaResearch Institute of Virology, Tashkent, Uzbekistan.
Ilham NorbaevFund of the State Medical Insurance of Jizzakh Region, Jizzakh, Uzbekistan.
Umar PrimovBukhara Regional Infectious Diseases Hospital, Bukhara, Uzbekistan.
Dilorom Ahrarova4th City Pediatric Infectious Diseases Hospital, Tashkent, Uzbekistan.
Saidkhon SharapovResearch Institute of Virology, Tashkent, Uzbekistan.
Ulugbek YusupovBukhara State Medical Institute, Bukhara, Uzbekistan.
Renat LatipovResearch Institute of Virology, Tashkent, Uzbekistan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis article presents the results of a long-term study of the impact of rotavirus vaccination in Uzbekistan. Uzbekistan is the first country in the Central Asian region to introduce rotavirus vaccination into the national compulsory vaccination calendar. The study aimed to evaluate the impact of rotavirus vaccination on hospitalizations due to all-cause AGE and RVGE in children < 5 years of age in Uzbekistan.

methodsDetection of rotavirus antigen was performed using Rotavirus-Antigen-IFA-BEST "Vector Best" kit (Novosibirsk, Russia).

resultsThe total of 20,128 children under 5 years of age were hospitalized in sentinel hospitals with a diagnosis of acute gastroenteritis during the study period (2019-2020). Of this number of children, 4481 children (22.2%) were included in the study. Of 4481 children, 367 (8.2%) children tested positive for rotavirus. In our study, decrease in the rotavirus rate was noted in all age groups. The peak of rotavirus positivity occurred in the months of January and February.

conclusionThe average rotavirus-positive rate in the period (2019-2020) was 8.2% and the absolute percentage decrease was 18.1% compared to the pre-vaccination period (2005-2009) where the rotavirus-positive rate was 26.3%. The percentage of prevented cases averaged 68.8%.

Indexed as

RotavirusRotavirus InfectionsRotavirus VaccinesAntigens, ViralChildChild, PreschoolDiarrheaHospitalizationHumansInfantSentinel SurveillanceUzbekistanVaccinationAntigens, ViralRotavirus VaccinesAGEBukharaRotavirusRVGETashkentUMVVaccination

Identifiers

PMID37300641
PMCPMC10257161

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.